Ticker Details
ADMA Biologics Inc ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases.
IPO Date:	October 18, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.67B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.16 | 2.73%
Avg Daily Range (30 D):	$0.38 | 2.35%
Avg Daily Range (90 D):	$0.37 | 2.19%

Institutional Daily Volume
Avg Daily Volume:	1.65M
Avg Daily Volume (30 D):	2.44M
Avg Daily Volume (90 D):	2.42M

Trade Size
Avg Trade Size (Sh.):	177
Avg Trade Size (Sh.) (30 D):	91
Avg Trade Size (Sh.) (90 D):	85

Institutional Trades
Total Institutional Trades:	2,182
Avg Institutional Trade:	$3.41M
Avg Institutional Trade (30 D):	$3.37M
Avg Institutional Trade (90 D):	$3.49M
Avg Institutional Trade Volume:	.3M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.64M
Avg Closing Trade (30 D):	$6.59M
Avg Closing Trade (90 D):	$7.44M
Avg Closing Volume:	496.88K

News

Dec 28, 2025 @ 5:26 PM ANI Stock Is Up 49% This Past Year, Revenue Is Sur... Source: Jonathan Ponciano

Aug 7, 2025 @ 2:00 PM Plasma Derived Medicine Market to Reach USD 37.4 B... Source: Towards Healthcare

Jul 30, 2025 @ 11:00 AM ADMA Biologics to Report Second Quarter 2025 Finan... Source: Adma Biologics, Inc.

May 6, 2025 @ 8:11 PM 3 Mid-Cap Medical Stocks Outperforming the Market Source: Marketbeat.Com

Apr 7, 2025 @ 11:00 AM ADMA Biologics Statement on Tariffs Source: N/A

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$.62	$.21	$.62
Diluted EPS	$.6	$.2	$.6
Revenue	$510.17M	$139.16M	$510.17M
Gross Profit	$292.77M	$88.82M	$292.77M
Net Income / Loss	$146.93M	$49.38M	$146.93M
Operating Income / Loss	$191.44M	$62.75M	$191.44M
Cost of Revenue	$217.41M	$50.35M	$217.41M
Net Cash Flow	$-15.52M	$26.25M	$-15.52M
PE Ratio	0.00